Skip to content
Screener

Prime Medicine PRME Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$856.0KMiss by $1.5M
EPS-$0.28Miss by $0.04
Revenue estimate$2.3M
EPS estimate-$0.24

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.23

Financials

Q1 2026

Income statement

See full
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$628.32M+141%
Enterprise value$665.04M+141%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Segments

By segment

See full
Reportable Segment$856.0K-41.1%

FAQ

When did Prime Medicine report Q1 2026 earnings?
Prime Medicine (PRME) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Prime Medicine's Q1 2026 revenue and EPS?
Prime Medicine reported revenue of $856.0K and eps of $-0.28 for Q1 2026.
Did Prime Medicine beat estimates in Q1 2026?
Revenue missed the consensus estimate of $2.3M by $1.5M. EPS missed the consensus estimate of $-0.24 by $0.04.
How did Prime Medicine's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 41.1% from $1.5M a year earlier and eps grew 30.0% from $-0.40.
Where can I find Prime Medicine's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-031719) and the 10-Q periodic report (0001628280-26-031726) directly on SEC EDGAR. The filing index links above go to sec.gov.